Neuronetics(US:STIM)2023-11-07 19:33Market Opportunity & Prevalence - The company addresses a significant market with 21 million US adults suffering from Major Depressive Disorder (MDD) and 4 million with Obsessive-Compulsive Disorder (OCD)[10] - Approximately 64 million US adults are poorly served by current antidepressant medications [13] - Market research indicates that 67% of patients with MDD are unhappy with their current treatment and willing to ask their physician about NeuroStar[38] Clinical Efficacy & Differentiation - NeuroStar demonstrates clinical efficacy with 83% response and 62% remission rates validated by a large outcomes registry [16] - A real-world study showed 62% of patients experienced significant relief in depression symptoms [30] - NeuroStar has patented contact sensing technology that ensures consistent TMS dose delivery, addressing a potential 40% loss of TMS dose with even 1 mm movement away from the head [34, 51] - NeuroStar has increased brand awareness by 33% in 2022 [22] Financial Performance - Q3 2023 revenue reached $179 million, an 8% increase from Q3 2022 [104] - The company estimates that treating approximately 12 patients can recoup the capital investment for physicians [65] - The company estimates that one patient per month can equal $100000 in practice revenue [87] - The company estimates to cover 95% of total private payor covered lives in the US for MDD and Anxious Depression [63]